The pharmaceutical industry is constantly evolving and making headlines. Here are a few stories in the news recently.
Gilead Purchases Kite Pharma for $11.9 Billion
Set to close in Q4 2017, Gilead’s acquisition is the culmination of an effort to diversify their pipeline from hepatitis medications and become a player in the development of personalized cell-based cancer therapies. Approval of Kite’s CAR-T cell therapy for refractory aggressive non-Hodgkin lymphoma is also expected in Q4.
Read more at The New York Times.
HPV Vaccination Rate Continues to Climb
60% of US teens have received at least one dose of the HPV vaccine, with the gap between girls and boys narrowing, according to the CDC. Our post details how researchers can utilize anti HPV T cells and HPV peptides to study the disease and search for new vaccinations or treatments.
Read more in the press release.
Richard Sherman Partners with Oxeia on Concussion Drug Research
A Seattle hero on the field, Richard Sherman is also making plays off the field as an advisory board member for Oxeia Biopharmaceuticals, developers of concussion treatment OXE-103. Oxeia, whose concussion treatment uses a naturally occurring hormone peptide (ghrelin), is preparing for phase 2 clinical studies.
Read more at FiercePharma.